Western University

Scholarship@Western
2015 Undergraduate Awards

The Undergraduate Awards

2015

Expression of HIV-1 Gag and Env Genes Using the
Vesicular Stomatitis Virus Vector System
Justine Baek
Western University, justinembaek@gmail.com

Follow this and additional works at: https://ir.lib.uwo.ca/ungradawards_2015
Part of the Medical Sciences Commons
Recommended Citation
Baek, Justine, "Expression of HIV-1 Gag and Env Genes Using the Vesicular Stomatitis Virus Vector System" (2015). 2015
Undergraduate Awards. 19.
https://ir.lib.uwo.ca/ungradawards_2015/19

Expression of HIV-1 gag and env genes using the vesicular stomatitis
virus vector system

Abstract
Traditional vaccine methods have long been employed to control widespread infectious
diseases, but so far, all commercially available vaccine strategies have been inadequate in efforts
to develop an effective therapeutic HIV vaccine. However, recent advancements in
immunological research have lead to the generation of novel vaccine strategies, one of which is
the recombinant virus vaccine, a method of particular interest that has shown promise in the
clearance of HIV infection within HIV-positive patients who have retained immunocompetence.
This study examined the stability of the expression of HIV-1 genes, gag and env, through a
recombinant virus vector, a recombinant vesicular stomatitis virus (VSV), a temperaturesensitive mutant genetically modified to contain the select HIV-1 genes (VSVInd(GML)HIV1gag-env). For SDS-PAGE, incubation was at 31 °C and 37 °C, the permissible and semipermissible growth conditions respectively for VSVInd(GML) temperature-sensitive mutants.
Western blot analysis was used to quantitate levels of protein expression of full VSV proteins,
Gag and Env, using a primary rabbit antibody of anti-VSV anti-serum and a secondary anti-IgG
from rabbit, a primary antibody of anti-p24 anti-serum and a secondary anti-IgG from rabbit, and
a primary goat antibody of anti-gp120, and a secondary anti-IgG from goat. Results indicated
that the VSVInd(GML) vector system allowed for high levels of expression of HIV-1 gag and env
genes. It is known that the expression of these genes induces the production of major neutralizing
antibodies and the stimulation of cytotoxic T lymphocytes, revealing the potential to use a
genetically modified recombinant VSV as a universal vector for the development of recombinant
virus vaccines. Specifically, the VSVInd(GML) mutant vector is thus an attractive candidate for
the viral vector of a therapeutic HIV vaccine system.
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Background and Rationale
According to the World Health Organization report in 2013, HIV has infected over 70
million people and 36 million have died from AIDS-related illnesses since 1981. Additional
reports from United Nations AIDS disclosed that 2.3 million were newly infected in 2012, adding
to a total of 35.3 million people diagnosed with HIV infection as of 2013. HIV/AIDS is a rising
world epidemic and our search for a method to control the spread of this disease has presented
one of the most challenging problems of the past three decades.
Vaccines are one of the most effective methods of controlling infectious disease and
thus a central focus for HIV treatment has been on efforts to develop an effective therapeutic
vaccine that will clear HIV infection. There are three types of commercially available vaccine
strategies that are used to prevent many different viral diseases. These include the live-attenuated
virus vaccine, such as the measles and mumps vaccines, the killed whole-virus vaccine, which
has been used to prevent influenza virus and hepatitis A virus infection, and subunit vaccines,
such as human hepatitis B virus and human papilloma virus vaccines. However, these three
conventional vaccine strategies have so far proved inadequate for use as therapeutic HIV vaccine
systems, effectively demonstrating our limited and largely empirically-based knowledge of these
technologies and our lack of a comprehensive understanding of the immunological principles
underlying widespread infectious diseases such as HIV (Luo, Li, & Kang, 2003; Hanke, 2001;
Nature, 2009). Recent advancements however, have resulted in the generation of novel vaccine
strategies, one of which is the recombinant virus vaccine, a method that has shown to be
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promising in clearance of HIV infection within HIV-positive patients who have retained
immunocompetence.

Recombinant virus vaccines depend on the use of a viral vector to carry genes of interest,
such as HIV genes, and express them in the body to activate CD8 positive cytotoxic T
lymphocytes (CTLs). Development of a therapeutic HIV vaccine to clear persistently infected
cells centers around the stimulation of adaptive host immune responses, in particular, the
induction of antibody-dependent cellular cytotoxicity and the activation of viral-specific CTLs
to destroy and clear HIV-infected cells (Kang, Luo, Wainberg, & Li, 1999). In particular, CTL
response is considered a major immune defense mechanism required for recovery from nearly
all viral infections (Luo et al., 1998). It is not desirable to use live HIV for CTL activation, but
through a recombinant virus vaccine, it is possible to express selected HIV genes, which will
activate HIV-specific CTLs.
The stimulation of HIV-specific CTLs also depends on the HIV genes chosen for
expression through the recombinant viral vector. HIV is a retrovirus with a genome expressing
three major structural proteins, Gag (capsid protein, matrix protein), Pol (reverse transcriptase,
RNase H, Integrase, protease) and Env (gp120 and gp41) (Goff, 2006). Particularly relevant are
HIV-1 gag and env genes of which can play critical roles in the induction of adaptive-host
immune responses (Kang, Luo, Wainberg, & Li, 1999). Gag, group-specific antigen, facilitates
viral assembly and maturation (Ono, Orenstein, & Freed, 2000). When gag is expressed without
pol in recombinant virus-infected cells, the precursor Gag55 assembles virus-like particles
(VLPs) that are non-infectious and mimic HIV virions (Luo, Li, Dales, &, Kang, 1994). Env,
envelope, comprises the Gp120 and Gp41 glycoproteins present on the surface of HIV as a trimer
(Wu et al., 2009). Env precursor protein, Gp160, is synthesized in the endoplasmic reticulum and
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then transported to the Golgi where it is cleaved into Gp120 and Gp41 by cellular proteases. The
surface protein, Gp120, attaches to the cellular receptors, CD4 and chemokine receptors, of
susceptible cells to initiate infection. In a study performed by Luo et al. (1998), it was found that
HIV-1 Gag particles carrying multiple T-cell epitopes of Gp120 induced strong CTL responses.
In a related study, Kang et al., (1999) demonstrated that HIV-1 gag-env VLPs resulted in high
CTL activity. HIV-1 gag and env genes have thus been identified as strong candidates for use in
an HIV/AIDS vaccine system and are therefore the genes of interest for this experiment.
In this study, the viral vector selected for HIV-1 gene expression was an attenuated
recombinant vesicular stomatitis virus (VSV), a member of the Rhabdoviridae family. VSV
infects cattle, horses, and swine and, in humans, infection results in asymptomatic or mild flulike symptoms such as fever and malaise (Wu, Kim, & Kang, 2009). VSV has a negative-sense
RNA genome containing 11,161 nucleotides, which encode five major viral structural proteins,
the nucleocapsid protein (N), the phosphoprotein (P), the matrix protein (M), the glycoprotein
(G), and the large protein (L) (Wagner, 1987; Lyles & Rupprecht, 2006; An, Kim, Wu, & Kang,
2013).
VSV presents an attractive viral vector system due to its wide host range, rapid
replication processes, and mild pathogenicity in humans (An et al., 2013). Kim and Kang (2007)
found that mutations introduced into the M gene of VSV result in an attenuated virus that exhibits
reduced inhibitory effects on host cell gene expression and results in significantly less cytopathic
effects within infected cell lines, a finding allowing for the production of avirulent and
temperature-sensitive VSV mutants. Most valuable is the existence of VSV in two serotypes;
Indiana (VSVInd) and New Jersey (VSVNJ). Wu et al. (2009) found that both serotypes have the
capacity to stably express foreign genes and exhibit no cross-neutralization, revealing the
potential for use of both VSV serotypes in a prime and boost method of vaccine delivery.
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In order for the recombinant VSV vector to be used for an effective therapeutic HIV
vaccine, the VSV vector system must be capable of stably expressing the HIV genes carried, an
issue appraised in this study. In this research, I evaluated the expression of HIV-1 gag and env
genes by employing VSVInd(GML), an avirulent and temperature-sensitive mutant vector system.
High levels of HIV-1 gag and env gene expression by VSVInd(GML) indicate the potential for
use of this viral vector system to activate CTLs and therefore confer immunity against infection
through a therapeutic HIV vaccine. In this study, I describe the construction of the recombinant
VSVInd(GML) vector, the recovery of the recombinant VSVInd(GML) mutant containing HIV-1
gag and env genes by reverse genetics, and the quantitation of levels of protein expression in
cells infected with the recombinant VSVInd(GML) containing gag and env genes.
Hypothesis
It was hypothesized that the recombinant VSVInd(GML) vector would successfully
express HIV-1 gag and env genes based on the reputation of the recombinant VSV as a tolerant
viral vector that has already been identified as having the acute ability to effectively express a
range of foreign genes, such as those of Marburg and Ebola viruses (Mire et al., 2012).
Quantitating the expression levels of HIV-1 Gag and Env proteins through the VSVInd(GML)
vector system will indicate the potential for application of a recombinant VSV mutant as a major
player in prospective therapeutic HIV vaccine development.

Experimental Methods
(1) Plasmid Construction
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The recombinant VSVInd(GML)HIV-1gag-env vector was provided for this experiment;
independent construction of the vector was not performed. However, the method of recombinant
vector construction needs to be briefly addressed for clear understanding of the results.
VSVInd(GML), an avirulent and temperature-sensitive mutant, was produced in the Kang
Laboratory through the introduction of mutations at G21E, M51R, and L111A. Fusion of HIV-1
gag and env genes created a gag-env hybrid gene. The gag gene insert also contained 171
nucleotides that coded for T cell epitopes. The HIV-1 gag-env hybrid gene was inserted into the
VSVInd(GML) genome between G and L genes of VSV by restriction enzyme Mlu1.

Figure 1. Construction of recombinant VSVInd(GML)HIV-1gag-env; insertion of HIV-1 gag-env hybrid gene
into VSVInd(GML) mutant genome by restriction enzyme Mlu1. TCE (T cell epitopes from gp41, gp120, and
Nef) was attached to the C-terminus of Gag protein. The env gene contains the honeybee melittin signal
peptide gene. The total gag-env gene insert is approximately 4,300 nucleotides.

(2) Cell culturing
Baby Hamster Kidney21 (BHK21) cells were used to amplify recombinant
VSVInd(GML)HIV-1gag-env. The cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) containing 5.0% fetal bovine serum (Gibco BRL), antibiotics penicillin (100 μg/mL),
streptomycin (100 μg/mL), and kanamycin (100 μg/mL), and L-Glutamine (2 mM). The cells
were incubated in a 5.0% CO2 incubator at 37 °C for 17 hours and passaged when 100%
confluent.

7

(3) Transformation of E. coli DH5α
Competent Cell Preparation
E. coli DH5α colonies were streaked on a SOB agar media without antibiotics and
incubated overnight at 37 °C. Five isolated colonies were transferred into 100 mL of SOB liquid
media without antibiotics and grown using a shaking incubator set to 210 rpm at 37 °C. Cells
were recovered by centrifugation at 4500 rpm at 4 °C for 10 minutes.

Transformation
E. coli DH5α cultures were first transformed with the plasmids N, P, L, and
VSVInd(GML)HIV-1gag-env according to the Molecular Cloning Manual (Sambrook & Russell,
2001). Plasmids diluted to 1 ng/μL were added into individual 200 μL aliquots of competent
cells. A heat shock of 42 °C was then administered. Cells were shaken at 210 rpm and incubated
at 37 °C for 1 hour. 200 μL of the transformed cells were spread onto lysogeny broth (LB) agar
media with antibiotics and incubated at 37 °C.

(4) DNA extraction by maxi-preparation
E. coli DH5α colonies transformed with plasmids N, P, L, and VSVInd(GML)HIV-1gagenv were screened for successful recombination. Positive clones were confirmed using restriction
enzyme mapping with digestion by enzyme, Mlu1. Three transformed colonies for each plasmid
were subcultured individually in 2 mL of LB with ampicillin and shaken at 210 rpm at 37 °C for
17 hours. The subcultures were recovered by centrifugation at 5000 rpm at 4 °C for 10 minutes.
The plasmid DNAs were purified and amplified to large quantities by the MAXIprep protocol
(Sambrook & Russell, 2001) using Solution I [50 mM glucose, 25 mM Tris HCl (pH 8.0), 10
mM EDTA (pH 8.0) with the addition of lysozyme [1 mg/1 mL], Solution II [1% SDS, 0.2 M
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NaOH], and Solution III [7.5 M ammonium acetate]. DNA gel electrophoresis was performed to
run extracted plasmid DNA alongside control plasmid DNA to verify successful extraction from
bacterial cultures.

(5) Recovery of VSVInd(GML)HIV-1gag-env by reverse genetics
Transfection was performed using BHKT7 cells and Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s specifications in order to recover the recombinant
VSVInd(GML)HIV-1gag-env by the VSV recovery protocol (Kim & Kang, 2007). Confluent
BHKT7 cells were transfected with 19.4 μg of the plasmid containing VSVInd(GML)HIV-1gagenv and co-transfected with 10 μg of pKS-HP, 10 μg of pKS-HN, and 5 μg of pKS-HL plasmid
DNA. VSV-specific RNA polymerase was expressed through transcription of N, P and L plasmid
DNA by T7 RNA polymerase and N, P, and L mRNAs were translated by Internal Ribosome
Entry Sites (IRES). VSVInd(GML)HIV-1gag-env was transcribed and replicated by VSV-specific
RNA polymerase (N, P, L), trimmed by HDV ribozyme, and assembled as the recombinant virus.
Incubation was at 31 °C in a 5% CO2 incubator because the recombinant VSVInd(GML)HIV1gag-env is a temperature-sensitive mutant. The culture media was harvested when 80% of cells
showed cytopathic effects (CPE), observed 96 hours post-transfection.

(6) Purification and determination of viral titer by plaque assay
Recovered virus, VSVInd(GML)HIV-1gag-env, was purified by three times plaque
picking on BHK21 cells. The viral titer was then determined by a plaque assay in order to
administer an infection at multiplicity of infection (MOI) of 0.1 to propagate the recovered
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VSVInd(GML)HIV-1gag-env and attain a viral stock. Recovered VSVInd(GML)HIV-1gag-env
was first diluted 10-4, 10-5 and 10-6 times. A 6-well plate of confluent Vero cells was inoculated
with 100 μL of each dilution and incubated at 37 °C for 17 hours. The resulting plaque numbers
were counted and determined the virus titer. Confluent BHK21 cells were infected at an MOI of
0.1 with serum-free DMEM for propagation to attain a viral stock. A second plaque assay titration
was performed repeating the same procedure in order to determine the viral titer of the viral stock
for infection at an MOI of 6 to prepare the cell lysate for SDS-PAGE and Western blot analysis.

(7) SDS-PAGE and Western blot analysis
Infections at an MOI of 6 of confluent BHK21 cells were performed with
VSVInd(GML)HIV-1gag-env and VSVInd(GML) without an insert as a negative control.
Incubation was at 31 °C and 37 °C, the permissible and semi-permissible growth conditions for
VSVInd(GML) temperature-sensitive mutants. The protein in the cell lysate obtained from these
infections was quantitated by UV spectrophotometry. The infected cell lysates were used to
perform an SDS-PAGE followed by Western blot analysis. Blotting was performed using TBST buffer (0.1% Tween). Detection during Western blotting was performed to quantitate the
expression of VSV proteins, Gag, and Env consecutively. For detection of VSV protein
expression, a primary rabbit antibody of anti-VSV anti-serum was used with a secondary antiIgG from rabbit. Detection of Gag expression was performed with a primary rabbit antibody,
anti-p24 anti-serum, and a secondary anti-IgG from rabbit. Detection of Env was then performed
with primary goat antibody, anti-gp120, and a secondary anti-IgG from goat.

Results
(1) Gel electrophoresis of extracted DNA by maxi-preparation
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DNA gel electrophoresis was used to verify successful extraction of each plasmid. DNA
gel electrophoresis was performed with DNA plasmids N, P, and L (Fig. 1) and the recombinant
vector, VSVInd(GML)HIV-1gag-env (Fig. 2). Samples of extracted DNA plasmids were
electrophoresed alongside corresponding stock control plasmids. Electrophoresis results showed
that the fragment sizes of extracted plasmids with marker plasmids were identical, indicating the
successful extraction of these plasmids from bacterial cultures.

16.0
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kbp
Figure 3. DNA gel electrophoresis of
control of
stock
andstock
extracted plasmid DNA
Figure 2. DNA gel electrophoresis
control
of
VSV
(GML)HIV-1gag-env
; lane 1Ind
and extracted plasmid DNA of N, P, and L.
control; lane 2- extracted.

(2) Recovery of VSVInd(GML)HIV-1gag-env

by reverse genetics
Bacteriophage T7 RNA polymerase is constitutively expressed in BHKT7 cells and this
RNA polymerase transcribes the transfected pVSVInd(GML)HIV-1gag-env cDNA genome and
co-transfected N, P and L plasmids. An Internal Ribosome Entry Site (IRES) allowed translation
of VSV N, P, and L proteins, the VSV-specific RNA polymerase. After initial transcription of
the recombinant VSVInd(GML)HIV-1gag-env genome by T7 RNA polymerase, it was replicated
and transcribed by VSV-specific RNA polymerase (N, P, and L proteins) and the recombinant
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VSVInd(GML)HIV-1gag-env was assembled and released as a recombinant virus. Culture media
containing the recombinant virus was harvested after observation of CPE in 80% of transfected
cells 96 hrs post-transfection.

Figure 4. Recovery of VSVInd(GML)HIV-1gag-env using Reverse Genetics. BHKT7 cells are
transfected with pVSVInd(GML)HIV-1gag-env and co-transfected with pN, pP, and pL. Culture
media was harvested from transfected cells after observation of 80% CPE (Buchholz, Fink &
Conzelmann, 1999).

(3) Determination of viral titer
The recombinant virus was propagated by infection at an MOI of 0.1. The viral titer of
the recombinant virus was determined by plaque assay on Vero cells. This procedure was
repeated to determine the viral titer of the amplified recombinant virus for a second infection of
BHK21 cells at MOI of 6. Resulting plaques and calculations for the determination of the viral
titer for the recovered virus and the viral stock are shown in Table 1.
Table 1
Determination of Viral Titer of VSVInd(GML)-HIV-1gag-env
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For Infection Counted
Plaques

Averaged
Plaques

Account for
Dilution Factor

Account for
Inoculation (100 μL)

Virus Titer
(pfu/mL)

MOI 0.1

22, 23

22.5

×106

×10

2.25 × 108

MOI 6

22, 33

27.5

×106

×10

2.75 × 108

(4) Quantitation of levels of protein expression by SDS-PAGE and Western blot analysis
Virus-infected cell lysates were analyzed by SDS-PAGE followed by Western blot
analysis for the quantitation of levels of viral protein expression. This was performed using cell
lysate prepared from infections with VSVInd(GML) containing no insert and VSVInd(GML)HIV1gag-env at 31 °C and 37 °C. Expression of HIV-1 Gag and Env proteins are marked by arrows
in the following figures.
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MW marker

MW marker

Figure 5. Expression of full VSVInd protein;
lane 1- VSVInd no inserts, lane 2VSVInd(GML)HIV-1gag-env

Figure 6. Expression of HIV-1 Gag55; lane 1VSVInd no inserts, lane 2- VSVInd(GML)HIV1gag-env

Env (gp160)

MW marker

Figure 7. Expression of HIV-1 Env (gp160);
lane 1- VSVInd no inserts, lane 2VSVInd(GML)HIV-1 gag-env

Discussion
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Results indicate that the VSVInd(GML) vector system allowed for high levels of
expression of HIV-1 gag and env genes. This finding reveals the potential to use a genetically
modified recombinant VSV as a universal vector for the development of recombinant virus
vaccines. The VSVInd(GML) mutant vector is thus an attractive candidate for the viral vector of
a therapeutic HIV vaccine. These major findings are concluded through the following analysis
of results:
(1) Gel electrophoresis of DNA extracted through maxi-preparation confirmed successful
extraction of pN, pP, pL, and VSVInd(GML)HIV-1gag-env from E. coli DH5α bacterial cultures.
This was established from the results of gel electrophoresis shown in Figures 1 and 2, which
depict identical fragment sizes for corresponding control and experimental plasmids run for each
DNA isolate.
(2) Recovery of VSVInd(GML)HIV-1gag-env using reverse genetics was accomplished with the
harvest of culture media containing the recombinant virus after observation of CPE in 80% of
transfected BHKT7 cells 96 hours post-transfection. Longer incubation time was required before
infected cells exhibited CPE because VSVInd(GML) is an attenuated, avirulent mutant.
(3) The results acquired from SDS-page and Western blot analysis indicated that VSVInd(GML)
containing no insert and VSVInd(GML)HIV-1gag-env both showed the same levels of VSVInd
protein expression at both permissive and semi-permissive temperatures, indicating that the
stability of VSVInd was not compromised by HIV-1 gene insertion. The high levels of expression
of both HIV-1 Gag and Env proteins by VSVInd(GML)HIV-1gag-env demonstrates that the
VSVInd(GML) vector system is capable of stably expressing HIV genes gag and env, revealing
the potential of VSVInd(GML) for use in a recombinant virus vaccine system.
In summary of the experimental procedures performed, the major steps of this study
comprised of vector construction with the insertion of an HIV-1 gag-env hybrid gene into the
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VSVInd(GML) genome, recovery of the recombinant virus by reverse genetics, and quantitation
of levels of protein expression in infected cell-lines. The procedures performed were successful
for obtaining the results needed to make conclusive evaluations of the VSVInd(GML) vector
system.
Similar results were shown in a study performed by Rose et al. (2000), who
demonstrated the use of a recombinant VSV to effectively express HIV-1 genes through the
sequential boosting of mice with recombinant VSV vectors encoding the HIV-1 Env protein.
Results revealed a great increase in the production of HIV-specific neutralizing antibodies. CTL
activation was not evaluated, but, a parallel study performed by Egan et al. (2004), demonstrated
a significant increase in CTL response in macaques with vaccination using recombinant VSVbased vectors expressing HIV-1 Env and simian-human immunodeficiency virus (SIV) Gag
proteins. The observations presented by these studies determined the same conclusions discussed,
identifying the ability of a recombinant VSV vector to express and process HIV-1 Gag and Env
proteins. Such results have also been expanded upon in a study performed by Wu, Kim, & Kang
(2009) who, in addition to highlighting the capability of the VSVInd(GML) vector system to
express HIV-1 genes, found that its counterpart, the VSV New Jersey serotype, also possesses
the ability to express HIV-1 gene, env (gp160), a finding that can be used in conjunction with
this study’s results to conclude the capability of both serotypes of VSV to express inserted HIV1 genes. This suggests the potential of employing both VSV vector systems in the development
of priming and boosting vaccines, using the VSV expression system to activate CD8 positive
CTLs.
To conclude, VSVInd(GML)HIV-1gag-env is capable of expressing HIV-1 Gag and
Env proteins at both permissive and semi-permissive temperatures. For application to a
recombinant virus vaccine system, it is desirable to develop a RNA virus vector capable of
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accommodating large foreign genes, allowing high levels of foreign gene expression. Therefore,
these positive results reveal the potential use of VSVInd(GML) as an efficient viral vector system
for a candidate therapeutic HIV vaccine to clear chronic HIV infection. This presents optimistic
prospects for the development of a vaccine system that can substitute the high prices of antiretrovirus therapeutic drugs with a cost-effective immunotherapy that will help clear infection
from millions of people diagnosed with HIV.

Future Work
Future research currently focuses on the application of recombinant virus vaccine
systems for the treatment of other infectious diseases such as the hepatitis C virus and even
bacterial diseases such as tuberculosis. The results from this experiment suggest that additional
projected studies of protective immune responses in animal models and the evaluation of the
side-effects of recombinant virus vaccine systems may be beneficial to expand our knowledge of
the immunological mechanisms underlying viral infections so that it may be possible to develop
more effective and economic anti-viral therapies.
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